C9091 HCPCS Level II code: Injection, sirolimus protein-bound particles, 1 mg
CMS terminated C9091: its last date of service was Jun 30, 2022. It stays here for looking up older claims; newer services need a current code.
Official description
C9091Injection, sirolimus protein-bound particles, 1 mg
Short description: Sirolimus, protein-bound,1mg
HCPCS · United States
Medicare details
The indicators CMS publishes with C9091 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Statute
- Type of service
- Other medical items or services
- BETOS category
- Chemotherapy
- Coverage statute
- 1833(t)
- Added
- Apr 1, 2022
- Terminated after
- Jun 30, 2022
Where C9091 sits
- 1C codesOutpatient prospective payment system
- 2Terminated C9091Injection, sirolimus protein-bound particles, 1 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
Is HCPCS code C9091 still valid?
No. CMS terminated C9091; its last date of service was Jun 30, 2022. It is listed for looking up services from before then. Use a current code for newer services.
Does Medicare cover C9091?
CMS lists C9091’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Statute”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside C9091
All C codesC9085Injection, avalglucosidase alfa-ngpt, 4 mgC9086Injection, anifrolumab-fnia, 1 mgC9087Injection, cyclophosphamide, (auromedics), 10 mgC9088Instillation, bupivacaine and meloxicam, 1 mg/0.03 mgC9089Bupivacaine, collagen-matrix implant, 1 mgC9090Injection, plasminogen, human-tvmh, 1 mgC9092Injection, triamcinolone acetonide, suprachoroidal (xipere), 1 mgC9093Injection, ranibizumab, via sustained release intravitreal implant (susvimo), 0.1 mgC9094Inj, sutimlimab-jome, 10 mgC9095Inj, tebentafusp-tebn, 1 mcgC9096Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgramC9097Inj, faricimab-svoa, 0.1 mg